Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
Ward Z, Stone J, Bishop C, Ivakin V, Eritsyan K, Deryabina A, Low A, Cepeda J, Kelly SL, Heimer R, Cook R, Altice FL, Litz T, Terlikbayeva A, El-Bassel N, Havarkov D, Fisenka A, Boshnakova A, Klepikov A, Saliuk T, Deshko T, Vickerman P. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis. The Lancet HIV 2021, 9: e42-e53. PMID: 34895484, PMCID: PMC8762142, DOI: 10.1016/s2352-3018(21)00274-5.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAgonist therapyAntiretroviral therapyPublic health approachHIV transmissionDrug useDynamic HIV transmission modelHealth approachIncremental cost-effectiveness ratioHIV transmission modelNational InstituteCost-effectiveness ratioCountry-specific costsHIV incidenceUNAIDS 90US National InstitutesART coverageWHO targetPWIDTherapyPay thresholdsInfectious diseasesCost savingsDrug abuseIncremental cost